EQT Life Sciences leads Series A funding round for maternal health company Nua Surgical
Summary
SteriCISION is the first self-retaining retractor designed specifically for Caesarean section (C-section) surgeries Proceeds will be used for regulatory approval and commercialization of the SteriCISION C-section retractorSTOCKHOLM, Dec. 6, 2024 /PRNewswire/ -- EQT Life Sciences is pleased to announce that the EQT Health Economics strategy has invested in Nua Surgical, an Irish medical device company innovating in maternal health. This innovative device is specifically designed to address the unique challenges of Caesarean-section (C-section) surgery.C-sections are the most common major surgical procedure globally, with over 30 million performed each year. This ergonomically designed and patented device provides fast, adjustable, and safe retraction, enabling clinicians to deliver the baby, repair tissue, and, crucially, identify bleeds. As a single-use sterile device, it aims to reduce the risk factors that lead to surgical complications, benefiting the patient, the clinician, and the healthcare system. This innovative device has the potential to improve the quality of care and reduce healthcare costs, making it a perfect fit for our EQT Health Economics strategy.